Related Experiment Video
Updated: Jul 12, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Radiation therapy options in kidney cancer
Nicholas G Zaorsky1, Alexander V Louie2, Shankar Siva3
1University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, USA.
Stereotactic body radiation therapy (SBRT) offers excellent local control for primary and metastatic renal cell carcinoma (RCC). This safe and effective treatment shows limited toxicity for patients with kidney cancer.
Area of Science:
- Oncology
- Radiation Oncology
Background:
- Renal cell carcinoma (RCC) presents challenges in primary and metastatic settings.
- Stereotactic body radiation therapy (SBRT) is an evolving treatment modality.
Approach:
- This review synthesizes current evidence on SBRT for primary and metastatic RCC.
- Examines efficacy, toxicity, and ongoing research.
Key Points:
- For primary RCC, SBRT achieves >95% local control with ≤5% grade 3-4 toxicity and minimal GFR impact.
- For metastatic RCC, SBRT demonstrates ~90% 1-year local control and ~1% grade 3-4 toxicity.
- Ongoing trials explore SBRT in combination with or as an alternative to systemic therapies.
Conclusions:
- SBRT is a safe and effective treatment for both primary and metastatic RCC.
- Further research is needed to address remaining unknowns in RCC prognostication, treatment selection, and delivery.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care

